BR112024002199A2 - Medicamentos de combinação compreendendo proteínas de fusão do hla - Google Patents
Medicamentos de combinação compreendendo proteínas de fusão do hlaInfo
- Publication number
- BR112024002199A2 BR112024002199A2 BR112024002199A BR112024002199A BR112024002199A2 BR 112024002199 A2 BR112024002199 A2 BR 112024002199A2 BR 112024002199 A BR112024002199 A BR 112024002199A BR 112024002199 A BR112024002199 A BR 112024002199A BR 112024002199 A2 BR112024002199 A2 BR 112024002199A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- hla
- combination drugs
- sirpa
- inhibitor
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 229940000425 combination drug Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 abstract 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150036449 SIRPA gene Proteins 0.000 abstract 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
medicamentos de combinação compreendendo proteínas de fusão do hla. a presente invenção se refere a medicamentos de combinação compreendendo polipeptídeos de cadeia pesada do hla (antígeno de leucócito humano) solúveis e um inibidor da interação entre cd47 e proteína reguladora de sinal alfa (sirpa), para uso em tratamento de câncer. aspectos adicionais da invenção se referem a um inibidor da interação entre cd47 e sirpa, para uso em pacientes recebendo tratamento com um polipeptídeo de cadeia pesada do hla solúvel de acordo com a invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21190003 | 2021-08-05 | ||
| PCT/EP2022/072133 WO2023012350A1 (en) | 2021-08-05 | 2022-08-05 | Combination medicaments comprising hla fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112024002199A2 true BR112024002199A2 (pt) | 2024-04-30 |
Family
ID=77411546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112024002199A BR112024002199A2 (pt) | 2021-08-05 | 2022-08-05 | Medicamentos de combinação compreendendo proteínas de fusão do hla |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4380605A1 (pt) |
| JP (1) | JP2024530040A (pt) |
| KR (1) | KR20240045260A (pt) |
| CN (1) | CN118103060A (pt) |
| AU (1) | AU2022322029A1 (pt) |
| BR (1) | BR112024002199A2 (pt) |
| CA (1) | CA3227617A1 (pt) |
| IL (1) | IL310617A (pt) |
| MX (1) | MX2024001691A (pt) |
| WO (1) | WO2023012350A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024165671A1 (en) * | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810099D0 (en) * | 1998-05-11 | 1998-07-08 | Isis Innovation | Novel molecule and diagnostic method |
| AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| ES2973099T3 (es) * | 2009-05-15 | 2024-06-18 | Univ Health Network | Composiciones y procedimientos para el tratamiento de cánceres hematológicos dirigidos a la interacción entre SIRP alfa y CD47 |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| CN113278077A (zh) | 2010-11-26 | 2021-08-20 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
| US20140242095A1 (en) | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| MX2014015825A (es) | 2012-06-28 | 2015-08-10 | Molecular Partners Ag | Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas. |
| EP3013361B1 (en) * | 2013-06-24 | 2021-10-06 | NexImmune, Inc. | Compositions and methods for immunotherapy |
| PT3656443T (pt) | 2015-01-21 | 2021-12-27 | Univ Leland Stanford Junior | Utilização de agonista trl e agente anti-cd47 para melhorar a fagocitose das células cancerígenas |
| AU2016214439B2 (en) | 2015-02-04 | 2019-05-02 | Universität Basel | Use of HLA-B27 homodimers for cancer treatment |
| JP6980196B2 (ja) | 2016-03-08 | 2021-12-15 | ウニヴェルズィテート チューリッヒ | Ｈｌａ−ｂ５７オープンコンフォーマー |
| JP7010439B2 (ja) | 2016-08-10 | 2022-01-26 | ウニヴェルズィテート チューリッヒ | ＭＨＣクラスＩａオープンコンフォーマー |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| CN110650976B (zh) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| ES2963157T3 (es) | 2017-07-26 | 2024-03-25 | Forty Seven Inc | Anticuerpos anti-SIRP-alfa y métodos relacionados |
| EP3807319A4 (en) * | 2018-06-13 | 2022-05-25 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
-
2022
- 2022-08-05 CN CN202280065738.9A patent/CN118103060A/zh active Pending
- 2022-08-05 KR KR1020247007369A patent/KR20240045260A/ko unknown
- 2022-08-05 WO PCT/EP2022/072133 patent/WO2023012350A1/en active Application Filing
- 2022-08-05 CA CA3227617A patent/CA3227617A1/en active Pending
- 2022-08-05 BR BR112024002199A patent/BR112024002199A2/pt unknown
- 2022-08-05 EP EP22764658.5A patent/EP4380605A1/en active Pending
- 2022-08-05 JP JP2024507945A patent/JP2024530040A/ja active Pending
- 2022-08-05 MX MX2024001691A patent/MX2024001691A/es unknown
- 2022-08-05 IL IL310617A patent/IL310617A/en unknown
- 2022-08-05 AU AU2022322029A patent/AU2022322029A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240045260A (ko) | 2024-04-05 |
| JP2024530040A (ja) | 2024-08-14 |
| WO2023012350A1 (en) | 2023-02-09 |
| CN118103060A (zh) | 2024-05-28 |
| MX2024001691A (es) | 2024-04-19 |
| EP4380605A1 (en) | 2024-06-12 |
| CA3227617A1 (en) | 2023-02-09 |
| IL310617A (en) | 2024-04-01 |
| AU2022322029A1 (en) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kawaguchi et al. | SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup | |
| BR112021017399A2 (pt) | Proteína de fusão bifuncional e uso farmacêutico da mesma | |
| CY1107042T1 (el) | Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων | |
| AU2019255744A8 (en) | IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof | |
| BR112024002199A2 (pt) | Medicamentos de combinação compreendendo proteínas de fusão do hla | |
| MX2022010803A (es) | Construcciones con un dominio sirp-alfa o sus variantes. | |
| AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
| PE20121636A1 (es) | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas | |
| BR112018072953A2 (pt) | polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos | |
| AU2021202634B2 (en) | Hla-b57 open conformers | |
| BR112023020123A2 (pt) | Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata | |
| BR112021026408A2 (pt) | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 | |
| BR112020023420A8 (pt) | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante | |
| CO2023001488A2 (es) | Proteínas de fusión del ligando para flt3 y métodos de uso | |
| ES2949372T3 (es) | Confórmeros abiertos del CMH de clase Ia | |
| CO2022010337A2 (es) | Anticuerpos monoclonales anti-sirpα y usos de los mismos | |
| Finotti et al. | A heat shock protein70 fusion protein with α1-antitrypsin in plasma of Type 1 diabetic subjects | |
| BR112021009912A2 (pt) | Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1 | |
| HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
| BR112022005426A2 (pt) | Polipeptídeos de fusão dap10/dap12 | |
| MX2023000243A (es) | Sialidasas recombinantes con sensibilidad reducida a la proteasa, proteinas de fusion de sialidasa y metodos para utilizarlas. | |
| BR112021026389A2 (pt) | Métodos e materiais para expansão direcionada de células t reguladoras | |
| BR112022025166A2 (pt) | Composto farmacêutico para o tratamento de doença cardiovascular aterosclerótica | |
| BR112023020802A2 (pt) | Polipeptídeo de ligação a gucy2c e usos do mesmo | |
| BRPI0409439A (pt) | peptìdeo tendo atividade de indução de ctl especìfico para htlv-i, peptìdeo de fusão, corpo de ligação de peptìdeo a proteìna, tetrámero de corpo de ligação de peptìdeo a proteìna, proteìna de fusão, dna, epìtopo de tax restringido por hal-a24, vacina, composição médica, agente de diagnóstico, anticorpo, vetor de expressão, célula hospedeira, e, método para induzir ctl que reconhece htlv-i |